01.08 15:41 | dpa-AFX: AbbVie Completes Acquisition Of Cerevel; Reaffirms Full-year Adj. EPS Guidance Range |
01.08 14:29 | dpa-AFX: *ABBVIE REAFFIRMS FY ADJ. EPS GUIDANCE IN $10.71-$10.91 RANGE |
01.08 14:28 | dpa-AFX: *ABBVIE STILL EXPECTS Q3 ADJ. EPS TO BE $2.92-$2.96 |
01.08 14:26 | dpa-AFX: *ABBVIE CLOSES ACQUISITION OF CEREVEL THERAPEUTICS; REAFFIRMS 2024 ADJ. EPS GUIDANCE |
29.07 12:17 | dpa-AFX: *DZ BANK HEBT FV FÜR ABBVIE AUF 204 (188) USD - 'KAUFEN' |
29.07 12:17 | dpa-AFX: *DZ BANK RAISES FV FÜR ABBVIE TO 204 (188) USD - 'BUY' |
26.07 08:46 | dpa-AFX: European Commission Approves AbbVie's Skyrizi To Treat Ulcerative Colitis |
26.07 08:05 | dpa-AFX: *ABBVIE : EC OKS SKYRIZI FOR TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS |
25.07 22:13 | MÄRKTE USA/Uneinheitlich nach Vortageseinbruch - Ford unter Druck |
25.07 18:15 | MÄRKTE USA/Börsen nach Vortageseinbruch mit Aufschlägen - Ford unter Druck |
25.07 14:00 | dpa-AFX: AbbVie Q2 24 Earnings Conference Call At 9:00 AM ET |
25.07 13:47 | dpa-AFX: ROUNDUP: AbbVie Boosts FY24 Outlook |
25.07 13:42 | dpa-AFX: AbbVie Q2 Profit Decreases, But Beats Estimates |
25.07 13:42 | dpa-AFX: *ABBVIE Q2 ATTRIBUTABLE NET EARNINGS $1.37 BLN VS $2.02 BLN PRIOR YEAR |
25.07 13:41 | dpa-AFX: *ABBVIE RAISES FY ADJ. EPS GUIDANCE FROM $10.61 - $10.81 TO $10.71 - $10.91 |
25.07 13:39 | dpa-AFX: *ABBVIE RAISES 2024 ADJ. EPS GUIDANCE RANGE FROM $10.61 - $10.81 TO $10.71 - $10.91 |
25.07 13:39 | dpa-AFX: *ABBVIE Q2 NET REVENUES OF $14.462 BLN, INCREASE OF 4.3% ON A REPORTED BASIS AND 5.6% ON OPERATIONAL BASIS |
25.07 13:38 | dpa-AFX: *ABBVIE Q2 EPS $0.77 ON A GAAP BASIS, A DECREASE OF 32.5% |
25.07 13:38 | dpa-AFX: *ABBVIE Q2 ADJ. EPS $2.65, DECREASE OF 8.9% |
12.07 14:48 | dpa-AFX: AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis |
|